A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
Phase 2
Completed
NCT06176963
| Condition | Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
|---|
| Status | Completed |
|---|
| Enrollment | 34 participants |
|---|
| Interventions | SB11 PFS |
|---|
| Start date | Nov 21, 2023 |
|---|
| Completion date | Nov 30, 2023 |
|---|
| Results posted | Dec 30, 2024 |
|---|
Summary
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB11 PFS with intravitreal injection to subjects with nAMD or Macular Oedema Secondary to RVO.
Percentage of Successful Task Completions
Day 1 · Percentage of successful task completion
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.